Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Eccles

Showing results (241-250 of 340) with videos related to

Pageof 34
Sort By:
Journal of Medical Genetics|November 21, 2022
UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: <i>RAD51C</i>, <i>RAD51D</i>, <i>BRIP1</i> and <i>PALB2</i>Helen Hanson, Anjana Kulkarni, Lucy Loong, et al.
Journal of Medical Genetics|December 12, 2018
Breast cancer risk in neurofibromatosis type 1 is a function of the type of <i>NF1</i> gene mutation: a new genotype-phenotype correlationIan M Frayling, Victor-Felix Mautner, Rick van Minkelen, et al.
Journal of Medical Genetics|March 15, 2020
Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary networkAlice Garrett, Alison Callaway, Miranda Durkie, et al.
Breast (Edinburgh, Scotland)|October 3, 2018
The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective reviewE Copson, A M Shaaban, T Maishman, et al.
Genome Research|July 7, 2005
Mutation scanning by meltMADGE: validations using BRCA1 and LDLR, and demonstration of the potential to identify severe, moderate, silent, rare, and paucimorphic mutations in the general populationKhalid K Alharbi, Mohammed A Aldahmesh, Emmanuel Spanakis, et al.
Journal of the National Cancer Institute|March 6, 2018
The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation CarriersBritta Weigelt, Rui Bi, Rahul Kumar, et al.
The Lancet. Oncology|January 17, 2018
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort studyEllen R Copson, Tom C Maishman, Will J Tapper, et al.
BJU International|May 27, 2018
Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutationsElizabeth K Bancroft, Sibel Saya, Elizabeth C Page, et al.
Journal of the National Cancer Institute|August 13, 2018
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel TestingHermela Shimelis, Holly LaDuca, Chunling Hu, et al.
Journal of Medical Genetics|July 5, 2005
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studiesA C Antoniou, P D P Pharoah, S Narod, et al.
Pageof 34

Showing results (241-250 of 340) with videos related to

Sort By:
Pageof 34
Journal of Medical Genetics|November 21, 2022
UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: <i>RAD51C</i>, <i>RAD51D</i>, <i>BRIP1</i> and <i>PALB2</i>Helen Hanson, Anjana Kulkarni, Lucy Loong, et al.
Journal of Medical Genetics|December 12, 2018
Breast cancer risk in neurofibromatosis type 1 is a function of the type of <i>NF1</i> gene mutation: a new genotype-phenotype correlationIan M Frayling, Victor-Felix Mautner, Rick van Minkelen, et al.
Journal of Medical Genetics|March 15, 2020
Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary networkAlice Garrett, Alison Callaway, Miranda Durkie, et al.
Breast (Edinburgh, Scotland)|October 3, 2018
The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective reviewE Copson, A M Shaaban, T Maishman, et al.
Genome Research|July 7, 2005
Mutation scanning by meltMADGE: validations using BRCA1 and LDLR, and demonstration of the potential to identify severe, moderate, silent, rare, and paucimorphic mutations in the general populationKhalid K Alharbi, Mohammed A Aldahmesh, Emmanuel Spanakis, et al.
Journal of the National Cancer Institute|March 6, 2018
The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation CarriersBritta Weigelt, Rui Bi, Rahul Kumar, et al.
The Lancet. Oncology|January 17, 2018
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort studyEllen R Copson, Tom C Maishman, Will J Tapper, et al.
BJU International|May 27, 2018
Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutationsElizabeth K Bancroft, Sibel Saya, Elizabeth C Page, et al.
Journal of the National Cancer Institute|August 13, 2018
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel TestingHermela Shimelis, Holly LaDuca, Chunling Hu, et al.
Journal of Medical Genetics|July 5, 2005
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studiesA C Antoniou, P D P Pharoah, S Narod, et al.
Pageof 34